Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients
Data from Certa Therapeutics' Phase 2 clinical trial with development candidate FT011 demonstrates clinically meaningful improvements for more than 60 percent of patients with scleroderma after 12 weeks of treatment; Clinically meaningful improvements were reported in CRISS (the key composite endpoint for systemic sclerosis) lung function, SHAQ-DI and Physician Global Assessment; The trial results also showed FT011 to be safe and well tolerated in this patient population; FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs; Certa's nov...
Source: singaporestar.com
